NCT05101746
Nitric Oxide Effect on Brain and Kidney in Pediatric Patients Undergoing Cardiopulmonary Bypass
Enrolling by Invitation
PHASE2Ages 0–1InterventionalTreatmentVanderbilt University Medical CenterInvestigator-initiated
~50 participants
Updated 2025-10-08 on ClinicalTrials.gov
What's tested:Nitric Oxide (NO) 20 part per million (ppm)Standard of care cardiopulmonary bypass
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Level of glial fibrillary acid protein (GFAP)
Measured over baseline to peak rewarming temperature of blood (approximately 3 hours)
+1 more outcome measured
Conditions
NCT05101746
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Vanderbilt University Medical Center
Nashville, Tennesseeno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- David P Bichell, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Level of glial fibrillary acid protein (GFAP)baseline to peak rewarming temperature of blood (approximately 3 hours)
GFAP will be measured via blood sample
- Level of neutrophil gelatinase-associated lipocalin (NGAL)baseline to 2 hours after CPB initiation (approximately 2 hours)
NGAL will be measured via blood sample